STP-938 is under clinical development by Step Pharma and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to GlobalData, Phase II drugs for Diffuse Large B-Cell Lymphoma have a 42% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how STP-938’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

STP-938 overview

STP-938 is under development for the treatment of autoimmune disorder such as rheumatoid arthritis, inflammation, solid tumors and hematological malignancies such as b-cell lymphoma including mantle cell lymphoma, diffuse large b-cell lymphoma, peripheral t-cell lymphomas, marginal zone b-cell lymphoma, follicular lymphoma and cutaneous t-cell lymphoma and mantle cell lymphoma. The drug candidate is administered through the oral route. The drug candidate acts by targeting CTP synthase 1 (cytidine triphosphate synthase).

Step Pharma overview

Step Pharma is a pharmaceutical company that discovers and develops novel therapeutics. The company develops a new class of oral nucleotide synthesis inhibitors against cytidine triphosphate synthase 1 (CTPS1) inhibitors. Its candidate is STP938, a small molecule inhibitor of CTPS1 currently in non-clinical development. Step Pharma’s product is used in the treatment of an array of auto-immune and oncology diseases, and blood cancers. The company collaborates with academic laboratories, clinical centers, and biopharmaceutical industry leaders to commercialize its programs and products. Its investors include Pontifax, Sygnature Discovery, Kurma Partners, and Idinvest Partners, among others. Step Pharma is headquartered in Archamps, Auvergne, France.

For a complete picture of STP-938’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.